News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Silica is a proven and highly effective anti-caking agent that has been used for decades
Subscribe To Our Newsletter & Stay Updated
